2.19
+0.11(+5.29%)
Currency In USD
| Previous Close | 2.08 |
| Open | 2.1 |
| Day High | 2.23 |
| Day Low | 2.09 |
| 52-Week High | 42.2 |
| 52-Week Low | 1.15 |
| Volume | 1.12M |
| Average Volume | 1.09M |
| Market Cap | 105.79M |
| PE | -1.38 |
| EPS | -1.59 |
| Moving Average 50 Days | 1.95 |
| Moving Average 200 Days | 8.17 |
| Change | 0.11 |
If you invested $1000 in Cassava Sciences, Inc. (SAVA) 10 years ago, it would be worth $1,288.24 as of July 10, 2025 at a share price of $2.19. Whereas If you bought $1000 worth of Cassava Sciences, Inc. (SAVA) shares 5 years ago, it would be worth $4,589.85 as of July 10, 2025 at a share price of $2.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
GlobeNewswire Inc.
Jun 30, 2025 11:00 AM GMT
Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASD
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
GlobeNewswire Inc.
May 01, 2025 11:30 AM GMT
As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01,
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
GlobeNewswire Inc.
Apr 21, 2025 8:30 PM GMT
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nerv